• Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=26095605).
  

PubMed=26095605; DOI=10.1016/j.stemcr.2015.05.010
Cusulin C., Chesnelong C., Bose P., Bilenky M., Kopciuk K., Chan J.A.W., Cairncross J.G., Jones S.J.M., Marra M.A., Luchman H.A., Weiss S.
Precursor states of brain tumor initiating cell lines are predictive of survival in xenografts and associated with glioblastoma subtypes.
Stem Cell Reports 5:1-9(2015)

PubMed=27006494; DOI=10.1158/1078-0432.CCR-15-1798
Lun X.-Q., Wells J.C., Grinshtein N., King J.C., Hao X.-G., Dang N.-H., Wang X.-L., Aman A., Uehling D., Datti A., Wrana J.L., Easaw J.C., Luchman H.A., Weiss S., Cairncross J.G., Kaplan D.R., Robbins S.M., Senger D.L.
Disulfiram when combined with copper enhances the therapeutic effects of temozolomide for the treatment of glioblastoma.
Clin. Cancer Res. 22:3860-3875(2016)

PubMed=30153289; DOI=10.1371/journal.pone.0202860
Yuan A.L., Ricks C.B., Bohm A.K., Lun X.-Q., Maxwell L., Safdar S., Bukhari S., Gerber A., Sayeed W., Bering E.A., Pedersen H., Chan J.A.W., Shen Y.-Q., Marra M., Kaplan D.R., Mason W., Goodman L.D., Ezhilarasan R., Kaufmann A.B., Cabral M., Robbins S.M., Senger D.L., Cahill D.P., Sulman E.P., Cairncross J.G., Blough M.D.
ABT-888 restores sensitivity in temozolomide resistant glioma cells and xenografts.
PLoS ONE 13:E0202860-E0202860(2018)